Comparative Metabolic Capabilities of CYP3A4, CYP3A5, and CYP3A7
Top Cited Papers
- 1 August 2002
- journal article
- research article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 30 (8) , 883-891
- https://doi.org/10.1124/dmd.30.8.883
Abstract
The human cytochromes P450 (P450) CYP3A contribute to the biotransformation of 50% of oxidatively metabolized drugs. The predominant hepatic form is CYP3A4, but recent evidence indicates that CYP3A5 contributes more significantly to the total liver CYP3A than was originally thought. CYP3A7 is the major fetal form and is rarely expressed in adults. To compare the metabolic capabilities of CYP3A forms for 10 substrates, incubations were performed using a consistent molar ratio (1:7:9) of recombinant CYP3A, P450 reductase, and cytochrome b5. A wide range of substrate concentrations was examined to determine the best fit to kinetic models for metabolite formation. In general, Km orS50 values for the substrates were 3 to 4 times lower for CYP3A4 than for CYP3A5 or CYP3A7. For a more direct comparison of these P450 forms, clearance to the metabolites was determined as a linear relationship of rate of metabolite formation for the lowest substrate concentrations examined. The clearance for 1′-hydroxy midazolam formation at low substrate concentrations was similar for CYP3A4 and CYP3A5. For CYP3A5 versus CYP3A4, clearance values at low substrate concentrations were 2 to 20 times lower for the other biotransformations. The clearance values for CYP3A7-catalyzed metabolite formation at low substrate concentrations were substantially lower than for CYP3A4 or CYP3A5, except for clarithromycin, 4-OH triazolam, and N-desmethyl diltiazem (CYP3A5 ≈ CYP3A7). The CYP3A forms demonstrated regioselective differences in some of the biotransformations. These results demonstrate an equal or reduced metabolic capability for CYP3A5 compared with CYP3A4 and a significantly lower capability for CYP3A7.Keywords
This publication has 18 references indexed in Scilit:
- Phenylalanine and Tryptophan Scanning Mutagenesis of CYP3A4 Substrate Recognition Site Residues and Effect on Substrate Oxidation and CooperativityBiochemistry, 2001
- Allosteric Behavior in Cytochrome P450-Dependent in Vitro Drug−Drug Interactions: A Prospective Based on Conformational DynamicsChemical Research in Toxicology, 2001
- Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A genePharmacogenetics, 2001
- cDNA Cloning and Initial Characterization of CYP3A43, a Novel Human Cytochrome P450Molecular Pharmacology, 2001
- CYP3A4 drug interactions: correlation of 10 in vitro probe substratesBritish Journal of Clinical Pharmacology, 1999
- Biotransformation of alprazolam by members of the human cytochrome P4503A subfamilyXenobiotica, 1999
- Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin*Clinical Pharmacology & Therapeutics, 1998
- Expression of Cytochrome P450 3A7 inEscherichia coli:Effects of 5′ Modification and Catalytic Characterization of Recombinant Enzyme Expressed in Bicistronic Format with NADPH-Cytochrome P450 ReductaseArchives of Biochemistry and Biophysics, 1997
- Functional properties of CYP2D6 1 (wild-type) and CYP2D6 7 (His324Pro) expressed by recombinant baculovirus in insect cellsNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1997
- Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamilyBiochemical Pharmacology, 1994